Should I buy or sell MediWound stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks .

What is MediWound's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for MediWound's shares. Their MDWD share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts .

How have MDWD shares performed in 2024?

MediWound's stock was trading at $10.17 at the beginning of the year. Since then, MDWD stock has increased by 55.1% and is now trading at $15.77. View the best growth stocks for 2024 here .

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our MDWD earnings forecast .

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. The biopharmaceutical company had revenue of $5.34 million for the quarter, compared to analyst estimates of $5.33 million. MediWound had a negative trailing twelve-month return on equity of 20.22% and a negative net margin of 35.94%.

When did MediWound's stock split?

Shares of MediWound reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Blackstone (BX) , Dynavax Technologies (DVAX) , Geron (GERN) , Idera Pharmaceuticals (IDRA) , Mastercard (MA) , SCYNEXIS (SCYX) , Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC) .

Who are MediWound's major shareholders?

MediWound's stock is owned by a number of retail and institutional investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.90%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free MDWD Stock Alerts

$15.77

-1.22 (-7.18%)

(As of 04/19/2024 ET)

Compare

Today's Range: $15.47
▼
$16.91
50-Day Range: $12.46
▼
$18.28
52-Week Range: $7.10
▼
$18.75

Volume: 106,833 shs
Average Volume: 104,016 shs
Market Capitalization: $149.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get MediWound alerts:

MediWound MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 102.9% Upside
$32.00 Price Target
Short Interest: Healthy
2.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.93) to ($1.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

674th out of 911 stocks

Medicinals & Botanicals Industry

6th out of 8 stocks

3.5

Analyst's Opinion

Consensus Rating
MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
MediWound has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.42% of the float of MediWound has been sold short.
Short Interest Ratio / Days to Cover
MediWound has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MediWound has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MediWound does not currently pay a dividend.
Dividend Growth
MediWound does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDWD.

1.3

News and Social Media Coverage

News Sentiment
MediWound has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for MediWound this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added MediWound to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediWound insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of MediWound is held by insiders.
Percentage Held by Institutions
46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MediWound are expected to grow in the coming year, from ($1.93) to ($1.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MediWound is -20.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MediWound is -20.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MediWound has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDWD Stock News Headlines

April 17, 2024 | finance.yahoo.com

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

March 24, 2024 | finance.yahoo.com

MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 23, 2024 | seekingalpha.com

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

March 21, 2024 | markets.businessinsider.com

Mediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic Expansion

March 21, 2024 | investorplace.com

MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023

March 21, 2024 | msn.com

MediWound reports mixed Q4 results; initiates FY24 outlook

March 21, 2024 | chron.com

MediWound: Q4 Earnings Snapshot

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 21, 2024 | globenewswire.com

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 20, 2024 | msn.com

MediWound Q4 2023 Earnings Preview

March 14, 2024 | globenewswire.com

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | finance.yahoo.com

Retail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as well

February 23, 2024 | msn.com

Nexobrid: A revolutionary treatment for burns to treat patients in few hours

February 12, 2024 | marketwatch.com

MediWound Shares Climb on Positive Data for EscharEx

February 12, 2024 | markets.businessinsider.com

MediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYL

February 12, 2024 | finance.yahoo.com

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

February 5, 2024 | finance.yahoo.com

MediWound to Participate in Two Upcoming Investor Conferences

January 15, 2024 | finance.yahoo.com

MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross

January 12, 2024 | markets.businessinsider.com

Mediwound Poised for Growth: Buy Rating Affirmed Amidst FDA Progress, Revenue Forecasts, and Expansion Potential

January 9, 2024 | finance.yahoo.com

Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet

January 9, 2024 | markets.businessinsider.com

MediWound: FDA To Review NexoBrid SBLA For Removal Of Eschar In Pediatric Patients

January 9, 2024 | msn.com

FDA accepts MediWound application for NexoBrid pediatric approval

January 9, 2024 | finance.yahoo.com

MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions

January 9, 2024 | finance.yahoo.com

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

December 28, 2023 | markets.businessinsider.com

MediWound Secures $6.7 Mln From US Department Of Defense For NexoBrid In Field-Care Burn Treatment

December 21, 2023 | finance.yahoo.com

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

See More Headlines

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/20/2024
Next Earnings (Estimated): 6/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medicinals & botanicals
Sub-Industry: N/A
Current Symbol: NASDAQ:MDWD
CUSIP: N/A
CIK: 1593984
Web: www.mediwound.com
Phone: 972779714100
Fax: 972-77-971-4111
Employees: 100
Year Founded: 2001

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $36.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +102.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,720,000.00
Net Margins: -35.94%
Pretax Margin: -34.95%
Return on Equity: -20.22%
Return on Assets: -10.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.59
Quick Ratio: 4.33

Sales & Book Value

Annual Sales: $18.69 million
Price / Sales: 8.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.43 per share
Price / Book: 4.60

Miscellaneous

Outstanding Shares: 9,490,000
Free Float: 8,619,000
Market Cap: $149.66 million
Optionable: Optionable
Beta: 0.93

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Lior Rosenberg M.D. (Age 78)
Co-Founder
Comp: $727k
Dr. Shmulik Hess Ph.D. (Age 51)
COO & Chief Commercial Officer
Mr. Yaron Meyer Adv. (Age 45)
Executive VP, General Counsel & Corporate Secretary
Comp: $240k
Mr. Barry J. Wolfenson (Age 57)
Executive Vice President of Strategy & Corporate Development
Dr. Ety Klinger MBA (Age 62)
Ph.D., Chief Research & Development Officer
Comp: $393k
Dr. Robert J. Snyder CWS (Age 74)
D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.
What is MediWound's stock price target for 2024?: 2 Wall Street research analysts have issued 12-month price targets for MediWound's shares. Their MDWD share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.
How have MDWD shares performed in 2024?: MediWound's stock was trading at $10.17 at the beginning of the year. Since then, MDWD stock has increased by 55.1% and is now trading at $15.77.
View the best growth stocks for 2024 here.
When is MediWound's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our MDWD earnings forecast.
How were MediWound's earnings last quarter?: MediWound Ltd. (NASDAQ:MDWD) issued its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. The biopharmaceutical company had revenue of $5.34 million for the quarter, compared to analyst estimates of $5.33 million. MediWound had a negative trailing twelve-month return on equity of 20.22% and a negative net margin of 35.94%.

When did MediWound's stock split?: Shares of MediWound reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of MediWound own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).
Who are MediWound's major shareholders?: MediWound's stock is owned by a number of retail and institutional investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.90%).
How do I buy shares of MediWound?: Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MediWound (MDWD) Stock Price, News & Analysis

MediWound MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MediWound Stock (NASDAQ:MDWD)

MDWD Stock Price History

MDWD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

MDWD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™